tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2025 Dec;19(12):e70158.
doi: 10.1111/irv.70158. Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain
Paloma Encinas[SUP] 1 2 [/SUP], Antonio Lalueza-Blanco[SUP] 3 [/SUP], Ana Isabel García-Vaquero[SUP] 4 5 [/SUP], Martha I Nelson[SUP] 6 [/SUP], Adolfo García-Sastre[SUP] 7 8 9 10 11 [/SUP], Gustavo Del Real[SUP] 1 [/SUP]
Affiliations
Swine influenza A viruses (SIVs) pose a zoonotic risk, with variants detected in humans in Europe. This study evaluated the efficacy of the 2021/2022 seasonal influenza vaccine against SIVs. Forty-six postvaccination human sera were tested via hemagglutination inhibition (HI) assay against Spanish SIV genotypes. Seroprotection rate (SPR, HI titer ≥ 40) was 76% (95% CI: 64-88) and 91% (95% CI: 83-99) for human vaccine strains H1 and H3, respectively. SPRs were 67% (95% CI: 53-81) for pandemic swine H1, 64% (95% CI: 50-78) for human seasonal-like H1, 17%-46% for Eurasian avian-like H1, 15% (95% CI: 5-25) for human seasonal-like H3 from the 1970s, and 83%-93% for human seasonal-like H3 from the 2000s SIVs.
Keywords: influenza A virus; pandemic risk; reverse zoonosis; swine; vaccine.
. 2025 Dec;19(12):e70158.
doi: 10.1111/irv.70158. Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain
Paloma Encinas[SUP] 1 2 [/SUP], Antonio Lalueza-Blanco[SUP] 3 [/SUP], Ana Isabel García-Vaquero[SUP] 4 5 [/SUP], Martha I Nelson[SUP] 6 [/SUP], Adolfo García-Sastre[SUP] 7 8 9 10 11 [/SUP], Gustavo Del Real[SUP] 1 [/SUP]
Affiliations
- PMID: 41431345
- DOI: 10.1111/irv.70158
Swine influenza A viruses (SIVs) pose a zoonotic risk, with variants detected in humans in Europe. This study evaluated the efficacy of the 2021/2022 seasonal influenza vaccine against SIVs. Forty-six postvaccination human sera were tested via hemagglutination inhibition (HI) assay against Spanish SIV genotypes. Seroprotection rate (SPR, HI titer ≥ 40) was 76% (95% CI: 64-88) and 91% (95% CI: 83-99) for human vaccine strains H1 and H3, respectively. SPRs were 67% (95% CI: 53-81) for pandemic swine H1, 64% (95% CI: 50-78) for human seasonal-like H1, 17%-46% for Eurasian avian-like H1, 15% (95% CI: 5-25) for human seasonal-like H3 from the 1970s, and 83%-93% for human seasonal-like H3 from the 2000s SIVs.
Keywords: influenza A virus; pandemic risk; reverse zoonosis; swine; vaccine.